ArticleFrontiers in oncology2025
Uncoupling protein 2 and signal transducer and activator of transcription 1 are targets of human papillomavirus oncoproteins and may be prognostic markers for cervical cancer development.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer, predominantly caused by persistent high-risk Human Papillomavirus (HPV) infection, remains a significant public health issue in developing countries. Identifying prognostic markers for patients with precursor lesions could improve clinical management and outcomes. Methods: We performed a comparative gene expression analysis between low- and high-grade cervical intraepithelial lesions, focusing on genes associated with inflammation and oxidative stress. STAT1 (Signal Transducer and Activator of Transcription 1) and UCP2 (Uncoupling Protein 2), known for their roles in other cancers, were selected for further validation. Immunodetection techniques were applied in both monolayer and organotypic cultures to assess the regulation of these proteins by HPV oncoproteins. Additionally, immunohistochemistry was conducted on two patient groups: those with precursor lesions plus cancer, and those with cervical cancer only. Results: In cultured HaCaT cells transduced with E6/E7 HPV oncogenes, expression levels of STAT1 and UCP2 changed, especially in organotypic cultures. In patient samples, both UCP2 and STAT1 levels increased with the severity of cervical precursor lesions, and their expressions showed a strong correlation. Notably, nuclear STAT1 expression, indicative of protein activation, was rare in cancer samples but correlated with poor prognosis. In contrast, positive UCP2 expression was linked to improved survival rates and reduced recurrence. Discussion: Our findings demonstrate that HPV oncoproteins modulate the expression of UCP2 and STAT1. These proteins may serve as valuable prognostic markers for patients with precursor cervical lesions, and UCP2 expression, in particular, could be beneficial for predicting outcomes in cervical cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.